GlassScriptPhysician profile
Arthur W Ide
NPI 1538128814
$1,109.69
in general payments reported to CMS, 2019-2025
24 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $81.27 · 2021: $156 · 2022: $200 · 2023: $175 · 2024: $274 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $192.84 | 2019-2025 | Dupixent |
| Genzyme Corporation | $115.15 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $102.58 | 2019-2024 | Winlevi |
| Lilly USA, LLC | $98.29 | 2019-2025 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $91.15 | 2022-2024 | Tremfya, Remicade, Stelara |
| Incyte Corporation | $83.45 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $66.69 | 2021-2024 | Aklief |
| Amgen INC. | $41.43 | 2020-2022 | |
| Biofrontera INC. | $40.42 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $30.96 | 2023-2025 | Ycanth |
| Abbvie INC. | $25.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.75 | 2024 | Spevigo |
| Celgene Corporation | $22.26 | 2019 | |
| Kyowa Kirin, INC. | $21.44 | 2024 | Poteligeo |
| Vyne Pharmaceuticals INC. | $20.30 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $18.21 | 2019 | |
| Dermavant Sciences, INC. | $15.97 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $15.76 | 2024 | Sotyktu |
| Leo Pharma INC. | $15.70 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $14.12 | 2019 | |
| Biocon Biologics INC | $13.97 | 2024 | Hulio |
| Arcutis Biotherapeutics, INC. | $13.59 | 2024 | Zoryve |
| Ucb, INC. | $13.50 | 2024 | Bimzelx |
| Pfizer INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Ide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.